IBDEI0OD ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11146,1,4,0)
 ;;=4^K71.4
 ;;^UTILITY(U,$J,358.3,11146,2)
 ;;=^5008798
 ;;^UTILITY(U,$J,358.3,11147,0)
 ;;=K75.81^^68^678^19
 ;;^UTILITY(U,$J,358.3,11147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11147,1,3,0)
 ;;=3^Nonalcoholic Steatohepatitis (NASH)
 ;;^UTILITY(U,$J,358.3,11147,1,4,0)
 ;;=4^K75.81
 ;;^UTILITY(U,$J,358.3,11147,2)
 ;;=^5008828
 ;;^UTILITY(U,$J,358.3,11148,0)
 ;;=K75.89^^68^678^16
 ;;^UTILITY(U,$J,358.3,11148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11148,1,3,0)
 ;;=3^Inflammatory Liver Disease,Oth Spec
 ;;^UTILITY(U,$J,358.3,11148,1,4,0)
 ;;=4^K75.89
 ;;^UTILITY(U,$J,358.3,11148,2)
 ;;=^5008829
 ;;^UTILITY(U,$J,358.3,11149,0)
 ;;=K76.4^^68^678^21
 ;;^UTILITY(U,$J,358.3,11149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11149,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,11149,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,11149,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,11150,0)
 ;;=K71.50^^68^678^25
 ;;^UTILITY(U,$J,358.3,11150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11150,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,11150,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,11150,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,11151,0)
 ;;=K71.51^^68^678^26
 ;;^UTILITY(U,$J,358.3,11151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11151,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/ Ascites
 ;;^UTILITY(U,$J,358.3,11151,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,11151,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,11152,0)
 ;;=K71.7^^68^678^29
 ;;^UTILITY(U,$J,358.3,11152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11152,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,11152,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,11152,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,11153,0)
 ;;=K71.8^^68^678^33
 ;;^UTILITY(U,$J,358.3,11153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11153,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,11153,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,11153,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,11154,0)
 ;;=K71.9^^68^678^34
 ;;^UTILITY(U,$J,358.3,11154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11154,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,11154,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,11154,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,11155,0)
 ;;=K75.2^^68^678^20
 ;;^UTILITY(U,$J,358.3,11155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11155,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,11155,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,11155,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,11156,0)
 ;;=K75.3^^68^678^13
 ;;^UTILITY(U,$J,358.3,11156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11156,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,11156,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,11156,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,11157,0)
 ;;=K76.6^^68^678^22
 ;;^UTILITY(U,$J,358.3,11157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11157,1,3,0)
 ;;=3^Portal Hypertension
 ;;^UTILITY(U,$J,358.3,11157,1,4,0)
 ;;=4^K76.6
 ;;^UTILITY(U,$J,358.3,11157,2)
 ;;=^5008834
 ;;^UTILITY(U,$J,358.3,11158,0)
 ;;=F20.3^^68^679^25
 ;;^UTILITY(U,$J,358.3,11158,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11158,1,3,0)
 ;;=3^Undifferentiated/Atypical Schizophrenia
 ;;^UTILITY(U,$J,358.3,11158,1,4,0)
 ;;=4^F20.3
 ;;^UTILITY(U,$J,358.3,11158,2)
 ;;=^5003472
 ;;^UTILITY(U,$J,358.3,11159,0)
 ;;=F20.9^^68^679^21
 ;;^UTILITY(U,$J,358.3,11159,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11159,1,3,0)
 ;;=3^Schizophrenia,Unspec
